Health tech firm Revvity misses Q3 revenue estimates, announces $1 bln buyback program

Reuters

Oct 27, 2025

Health tech firm Revvity misses Q3 revenue estimates, announces $1 bln buyback program

Overview

Revvity Q3 revenue of $699 mln missed analyst expectations
Adjusted EPS from continuing operations was $1.18, down from $1.28 last year
Company authorizes new $1 bln share repurchase program

Outlook

Revvity updates 2025 revenue guidance to $2.83-$2.88 bln due to currency changes
Company reaffirms 2025 organic growth guidance of 2% to 4%
Revvity raises 2025 adjusted EPS guidance to $4.90-$5.00

Result Drivers

STRATEGIC PARTNERSHIPS - CEO Prahlad Singh attributes Q3 performance to key innovations and strategic partnerships
SHARE REPURCHASE - Co authorizes new $1 bln share repurchase program, replacing prior program

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q3 Revenue	Miss	$698.94 mln	$700.45 mln (16 Analysts)
Q3 EPS		$0.40
Q3 Adjusted EPS continuing operations		$1.18

Press Release: ID:nBw7gg2X4a

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2578614959"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2578614959\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2578614959?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-27 18:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2578614959","market":"fut","top_or_hot":-1,"title":"Health tech firm Revvity misses Q3 revenue estimates, announces $1 bln buyback program","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Health tech firm Revvity misses Q3 revenue estimates, announces $1 bln buyback program</title></head><body><p><span>Overview</span></p><ul><li><p>Revvity Q3 revenue of $699 mln missed analyst expectations</p></li><li><p>Adjusted EPS from continuing operations was $1.18, down from $1.28 last year</p></li><li><p>Company authorizes new $1 bln share repurchase program</p></li></ul><p><span>Outlook</span></p><ul><li><p>Revvity updates 2025 revenue guidance to $2.83-$2.88 bln due to currency changes</p></li><li><p>Company reaffirms 2025 organic growth guidance of 2% to 4%</p></li><li><p>Revvity raises 2025 adjusted EPS guidance to $4.90-$5.00</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>STRATEGIC PARTNERSHIPS - CEO Prahlad Singh attributes Q3 performance to key innovations and strategic partnerships</p></li><li><p>SHARE REPURCHASE - Co authorizes new $1 bln share repurchase program, replacing prior program</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Revenue</p></td><td><p>Miss</p></td><td><p>$698.94 mln</p></td><td><p>$700.45 mln (16 Analysts)</p></td></tr><tr><td><p>Q3 EPS</p></td><td></td><td><p>$0.40</p></td><td></td></tr><tr><td><p>Q3 Adjusted EPS continuing operations</p></td><td></td><td><p>$1.18</p></td><td></td></tr></tbody></table><p>Press Release: <span>ID:nBw7gg2X4a</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Health tech firm Revvity misses Q3 revenue estimates, announces $1 bln buyback program</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHealth tech firm Revvity misses Q3 revenue estimates, announces $1 bln buyback program\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-27 18:11</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Health tech firm Revvity misses Q3 revenue estimates, announces $1 bln buyback program</title></head><body><p><span>Overview</span></p><ul><li><p>Revvity Q3 revenue of $699 mln missed analyst expectations</p></li><li><p>Adjusted EPS from continuing operations was $1.18, down from $1.28 last year</p></li><li><p>Company authorizes new $1 bln share repurchase program</p></li></ul><p><span>Outlook</span></p><ul><li><p>Revvity updates 2025 revenue guidance to $2.83-$2.88 bln due to currency changes</p></li><li><p>Company reaffirms 2025 organic growth guidance of 2% to 4%</p></li><li><p>Revvity raises 2025 adjusted EPS guidance to $4.90-$5.00</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>STRATEGIC PARTNERSHIPS - CEO Prahlad Singh attributes Q3 performance to key innovations and strategic partnerships</p></li><li><p>SHARE REPURCHASE - Co authorizes new $1 bln share repurchase program, replacing prior program</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Revenue</p></td><td><p>Miss</p></td><td><p>$698.94 mln</p></td><td><p>$700.45 mln (16 Analysts)</p></td></tr><tr><td><p>Q3 EPS</p></td><td></td><td><p>$0.40</p></td><td></td></tr><tr><td><p>Q3 Adjusted EPS continuing operations</p></td><td></td><td><p>$1.18</p></td><td></td></tr></tbody></table><p>Press Release: <span>ID:nBw7gg2X4a</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251027:nL1N3W80AP:1","article_id":"2578614959","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2578614959","pubTimestamp":1761559895,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Health tech firm Revvity misses Q3 revenue estimates, announces $1 bln buyback programOverviewRevvity Q3 revenue of $699 mln missed analyst expectationsAdjusted EPS from continuing operations was $1.1","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","RVTY":"REVVITY INC","BK4121":"生命科学工具和服务","BK4585":"ETF&股票定投概念"},"translate_title":"健康科技公司Revvity第三季度收入未达预期，宣布10亿美元回购计划","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RVTY":0.9},"content_text":"Health tech firm Revvity misses Q3 revenue estimates, announces $1 bln buyback programOverviewRevvity Q3 revenue of $699 mln missed analyst expectationsAdjusted EPS from continuing operations was $1.18, down from $1.28 last yearCompany authorizes new $1 bln share repurchase programOutlookRevvity updates 2025 revenue guidance to $2.83-$2.88 bln due to currency changesCompany reaffirms 2025 organic growth guidance of 2% to 4%Revvity raises 2025 adjusted EPS guidance to $4.90-$5.00Result DriversSTRATEGIC PARTNERSHIPS - CEO Prahlad Singh attributes Q3 performance to key innovations and strategic partnershipsSHARE REPURCHASE - Co authorizes new $1 bln share repurchase program, replacing prior programKey DetailsMetricBeat/MissActualConsensus EstimateQ3 RevenueMiss$698.94 mln$700.45 mln (16 Analysts)Q3 EPS$0.40Q3 Adjusted EPS continuing operations$1.18Press Release: ID:nBw7gg2X4aFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}